Bristol Myers Squibb (BMY) Other Operating Expenses (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Other Operating Expenses data on file, last reported at $4.0 billion in Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $4.0 billion, down 9.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.2 billion (down 8.34% YoY), and the FY2025 annual result was $21.6 billion, down 41.66% from the prior year.
• Other Operating Expenses fell to $4.0 billion in Q1 2026 per BMY's latest filing, from $6.3 billion in the prior quarter.
• Over five years, Other Operating Expenses peaked at $18.3 billion in Q1 2024 and troughed at $4.0 billion in Q1 2026.
• A 5-year average of $6.1 billion and a median of $5.3 billion in 2023 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses surged 308.54% in 2024, then slumped 76.04% in 2025.
• A 5-year view of Other Operating Expenses shows it stood at $4.8 billion in 2022, then increased by 10.08% to $5.3 billion in 2023, then soared by 30.24% to $6.8 billion in 2024, then decreased by 8.41% to $6.3 billion in 2025, then plunged by 36.41% to $4.0 billion in 2026.
• Business Quant data shows BMY's Other Operating Expenses at $4.0 billion in Q1 2026, $6.3 billion in Q4 2025, and $4.8 billion in Q3 2025.